CompletedPhase 3Phase 4ACTRN12608000447358
Pravastatin in Polycystic Kidney Disease
Effect of Pravastatin on Kidney Function in Polycystic Kidney Disease
Sponsor
Clifford Craig Medical Research Trust
Enrollment
100 participants
Start Date
Jan 1, 1998
Study Type
Interventional
Conditions
Summary
Polycystic kidney disease is a common cause of kidney failure Statins may slow kidney disease progression. This study aimed to assess whether pravastatin 20mg could slow the progression of kidney disease
Eligibility
Sex: Both males and femalesMin Age: 18 YearssMax Age: 85 Yearss
Inclusion Criteria1
- Polycystic kidney disease
Exclusion Criteria1
- Females of Child bearing potential
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Pravastatin 20mg orally daily for 2 years
Pravastatin 20mg orally daily for 2 years
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000447358
Related Trials
Well-Formulated Ketogenic Diet Polycystic Kidney Disease
NCT063256441 location
Early PKD Observational Cohort Study
NCT029367913 locations
Polycystic Kidney Disease Data Repository
NCT007921551 location
PKD Clinical and Translational Core Study
NCT018732351 location
Amnioinfusion for Fetal Renal Failure
NCT067282281 location